FDA demands new trial for Galvus

The FDA is demanding new data from Novartis for its diabetes drug Galvus, delaying any potential approval by a year. The agency is requiring Novartis to mount a new study of Galvus to assess kidney impairment. The decision is a significant setback for Novartis, which has avidly sought an approval of the drug. European regulators are currently considering Galvus for approval.

"We are confident in the safety and efficacy of Galvus and will continue working closely with the FDA to agree on what final actions are required to obtain U.S. approval," said James Shannon, global head of development at Novartis.

- check out the press release on the delay
- here's the AP report on the FDA's decision

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.